2020 Q4 Form 10-Q Financial Statement
#000117184320008002 Filed on November 16, 2020
Income Statement
Concept | 2020 Q4 | 2020 Q3 | 2019 Q3 |
---|---|---|---|
Revenue | $81.00K | $0.00 | $0.00 |
YoY Change | |||
Cost Of Revenue | $36.00K | ||
YoY Change | |||
Gross Profit | $45.00K | ||
YoY Change | |||
Gross Profit Margin | 55.56% | ||
Selling, General & Admin | $1.331M | $1.458M | $2.301M |
YoY Change | -40.42% | -36.64% | 75.65% |
% of Gross Profit | 2957.78% | ||
Research & Development | $678.0K | $1.286M | $3.954M |
YoY Change | -82.67% | -67.48% | -56.68% |
% of Gross Profit | 1506.67% | ||
Depreciation & Amortization | $0.00 | $56.00K | $72.00K |
YoY Change | -100.0% | -22.22% | -89.61% |
% of Gross Profit | 0.0% | ||
Operating Expenses | $2.009M | $2.744M | $6.255M |
YoY Change | -67.31% | -56.13% | -40.07% |
Operating Profit | -$1.964M | -$8.034M | -$6.255M |
YoY Change | -68.04% | 28.44% | |
Interest Expense | -$1.256M | $2.030M | -$14.86M |
YoY Change | -79.0% | -113.66% | 20.95% |
% of Operating Profit | |||
Other Income/Expense, Net | -$1.256M | $1.888M | -$14.90M |
YoY Change | -78.99% | -112.67% | 745050.0% |
Pretax Income | -$3.220M | -$6.146M | -$21.16M |
YoY Change | -73.43% | -70.95% | -6.91% |
Income Tax | |||
% Of Pretax Income | |||
Net Earnings | -$3.220M | -$6.146M | -$21.16M |
YoY Change | -73.44% | -70.95% | -6.91% |
Net Earnings / Revenue | -3975.31% | ||
Basic Earnings Per Share | |||
Diluted Earnings Per Share | -$233.2K | -$516.9K | -$254.6K |
COMMON SHARES | |||
Basic Shares Outstanding | 96.89M | 96.89M | |
Diluted Shares Outstanding |
Balance Sheet
Concept | 2020 Q4 | 2020 Q3 | 2019 Q3 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $27.92M | $11.55M | $20.23M |
YoY Change | 36.96% | -42.9% | 238.92% |
Cash & Equivalents | $26.55M | $11.55M | $19.50M |
Short-Term Investments | $1.372M | $20.36K | |
Other Short-Term Assets | $1.647M | $1.536M | $515.2K |
YoY Change | -11.62% | 198.14% | 134.18% |
Inventory | $14.00K | ||
Prepaid Expenses | $559.0K | $489.0K | |
Receivables | $619.0K | $625.0K | $995.9K |
Other Receivables | $0.00 | $0.00 | $0.00 |
Total Short-Term Assets | $30.20M | $13.71M | $21.74M |
YoY Change | 28.6% | -36.93% | 195.36% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $105.0K | $119.0K | $2.297M |
YoY Change | -95.34% | -94.82% | -24.36% |
Goodwill | |||
YoY Change | |||
Intangibles | $0.00 | $0.00 | |
YoY Change | |||
Long-Term Investments | $0.00 | ||
YoY Change | -100.0% | ||
Other Assets | $436.1K | ||
YoY Change | -26.33% | ||
Total Long-Term Assets | $105.0K | $119.0K | $7.886M |
YoY Change | -98.57% | -98.49% | -37.21% |
TOTAL ASSETS | |||
Total Short-Term Assets | $30.20M | $13.71M | $21.74M |
Total Long-Term Assets | $105.0K | $119.0K | $7.886M |
Total Assets | $30.30M | $13.83M | $29.63M |
YoY Change | -1.72% | -53.31% | 48.73% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $2.100M | $3.670M | $10.53M |
YoY Change | -78.55% | -65.16% | -20.04% |
Accrued Expenses | $105.0K | $81.00K | |
YoY Change | |||
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $1.503M |
YoY Change | -100.0% | -100.0% | |
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $2.248M | $3.751M | $12.04M |
YoY Change | -80.18% | -68.84% | -8.63% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | -100.0% | ||
Other Long-Term Liabilities | $2.340M | $1.208M | $18.90M |
YoY Change | -90.41% | -93.61% | -4.82% |
Total Long-Term Liabilities | $2.340M | $1.208M | $18.90M |
YoY Change | -90.41% | -93.61% | -12.39% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $2.248M | $3.751M | $12.04M |
Total Long-Term Liabilities | $2.340M | $1.208M | $18.90M |
Total Liabilities | $4.588M | $4.959M | $30.93M |
YoY Change | -87.16% | -83.97% | -10.96% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | -$140.4M | -$137.2M | |
YoY Change | |||
Common Stock | $162.2M | $142.6M | |
YoY Change | |||
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $25.72M | $8.873M | -$759.0K |
YoY Change | |||
Total Liabilities & Shareholders Equity | $30.30M | $13.83M | $29.63M |
YoY Change | -1.72% | -53.31% | 48.73% |
Cashflow Statement
Concept | 2020 Q4 | 2020 Q3 | 2019 Q3 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$3.220M | -$6.146M | -$21.16M |
YoY Change | -73.44% | -70.95% | -6.91% |
Depreciation, Depletion And Amortization | $0.00 | $56.00K | $72.00K |
YoY Change | -100.0% | -22.22% | -89.61% |
Cash From Operating Activities | -$4.214M | -$4.178M | -$6.152M |
YoY Change | -40.68% | -32.09% | -6.08% |
INVESTING ACTIVITIES | |||
Capital Expenditures | $0.00 | -$33.00K | -$17.00K |
YoY Change | -100.0% | 94.12% | -93.31% |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | -$1.372M | $0.00 | $3.383M |
YoY Change | 1375.27% | -100.0% | 5538.33% |
Cash From Investing Activities | -$1.372M | -$33.00K | $3.366M |
YoY Change | 295.39% | -100.98% | -1835.05% |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | $19.75M | $3.435M | $0.00 |
YoY Change | 228.97% | -100.0% | |
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 19.75M | $3.434M | 6.596M |
YoY Change | 177.43% | -47.94% | -5213.18% |
NET CHANGE | |||
Cash From Operating Activities | -4.214M | -$4.178M | -6.152M |
Cash From Investing Activities | -1.372M | -$33.00K | 3.366M |
Cash From Financing Activities | 19.75M | $3.434M | 6.596M |
Net Change In Cash | 14.99M | -$570.0K | 3.519M |
YoY Change | 5432.84% | -116.2% | -151.2% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$4.214M | -$4.178M | -$6.152M |
Capital Expenditures | $0.00 | -$33.00K | -$17.00K |
Free Cash Flow | -$4.214M | -$4.145M | -$6.135M |
YoY Change | -38.48% | -32.44% | -2.56% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2019Q1 | acst |
Atthemarket Sales Agreement Common Stock Maximum Amount
AtthemarketSalesAgreementCommonStockMaximumAmount
|
30000000 | |
CY2020Q2 | acst |
Atthemarket Sales Agreement Common Stock Maximum Amount
AtthemarketSalesAgreementCommonStockMaximumAmount
|
75000000 | |
CY2019Q1 | acst |
Atthemarket Sales Agreement Term
AtthemarketSalesAgreementTerm
|
P3Y | |
dei |
Amendment Flag
AmendmentFlag
|
false | ||
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--03-31 | ||
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q2 | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2021 | ||
dei |
Document Period End Date
DocumentPeriodEndDate
|
2020-09-30 | ||
dei |
Document Type
DocumentType
|
10-Q | ||
CY2020Q2 | acst |
Atthemarket Sales Agreement Underwriter Fees Percentage Of Sales
AtthemarketSalesAgreementUnderwriterFeesPercentageOfSales
|
0.03 | |
CY2020Q3 | acst |
Effect Of Translation Effect On Cash And Cash Equivalents
EffectOfTranslationEffectOnCashAndCashEquivalents
|
-31000 | |
CY2019Q3 | acst |
Effect Of Translation Effect On Cash And Cash Equivalents
EffectOfTranslationEffectOnCashAndCashEquivalents
|
-101000 | |
acst |
Effect Of Translation Effect On Cash And Cash Equivalents
EffectOfTranslationEffectOnCashAndCashEquivalents
|
-151000 | ||
acst |
Effect Of Translation Effect On Cash And Cash Equivalents
EffectOfTranslationEffectOnCashAndCashEquivalents
|
224000 | ||
CY2020Q3 | acst |
Fair Value Of Derivative Warrants Liability Reclassified To Equity
FairValueOfDerivativeWarrantsLiabilityReclassifiedToEquity
|
||
CY2019Q3 | acst |
Fair Value Of Derivative Warrants Liability Reclassified To Equity
FairValueOfDerivativeWarrantsLiabilityReclassifiedToEquity
|
9890000 | |
acst |
Fair Value Of Derivative Warrants Liability Reclassified To Equity
FairValueOfDerivativeWarrantsLiabilityReclassifiedToEquity
|
|||
acst |
Fair Value Of Derivative Warrants Liability Reclassified To Equity
FairValueOfDerivativeWarrantsLiabilityReclassifiedToEquity
|
9904000 | ||
CY2020Q3 | acst |
Increase Decrease In Unpaid Fixed Assets
IncreaseDecreaseInUnpaidFixedAssets
|
||
CY2019Q3 | acst |
Increase Decrease In Unpaid Fixed Assets
IncreaseDecreaseInUnpaidFixedAssets
|
17000 | |
acst |
Increase Decrease In Unpaid Fixed Assets
IncreaseDecreaseInUnpaidFixedAssets
|
|||
acst |
Increase Decrease In Unpaid Fixed Assets
IncreaseDecreaseInUnpaidFixedAssets
|
|||
CY2020Q3 | acst |
Increase Decrease In Working Capital
IncreaseDecreaseInWorkingCapital
|
2217000 | |
CY2019Q3 | acst |
Increase Decrease In Working Capital
IncreaseDecreaseInWorkingCapital
|
1244000 | |
acst |
Increase Decrease In Working Capital
IncreaseDecreaseInWorkingCapital
|
3395000 | ||
acst |
Increase Decrease In Working Capital
IncreaseDecreaseInWorkingCapital
|
868000 | ||
CY2020Q3 | acst |
Interest Payable Included In Payables
InterestPayableIncludedInPayables
|
||
CY2019Q3 | acst |
Interest Payable Included In Payables
InterestPayableIncludedInPayables
|
30000 | |
acst |
Interest Payable Included In Payables
InterestPayableIncludedInPayables
|
|||
acst |
Interest Payable Included In Payables
InterestPayableIncludedInPayables
|
30000 | ||
acst |
Proceeds From Nrcirap
ProceedsFromNRCIRAP
|
79000 | ||
CY2020Q3 | acst |
Stock Issued As Settlement
StockIssuedAsSettlement
|
||
CY2019Q3 | acst |
Stock Issued As Settlement
StockIssuedAsSettlement
|
||
acst |
Stock Issued As Settlement
StockIssuedAsSettlement
|
|||
acst |
Stock Issued As Settlement
StockIssuedAsSettlement
|
680000 | ||
CY2019Q2 | acst |
Stock Issued During Period Value Settlements
StockIssuedDuringPeriodValueSettlements
|
739000 | |
CY2019Q2 | acst |
Stock Issued During Period Value Warrant Exercises
StockIssuedDuringPeriodValueWarrantExercises
|
34000 | |
CY2019Q3 | acst |
Stock Issued During Period Value Warrant Exercises
StockIssuedDuringPeriodValueWarrantExercises
|
16518000 | |
CY2020Q2 | acst |
Write Off Of Deferred Financing Costs Of At The Market Program
WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram
|
122000 | |
CY2020Q3 | acst |
Write Off Of Deferred Financing Costs Of At The Market Program
WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram
|
142000 | |
CY2019Q3 | acst |
Write Off Of Deferred Financing Costs Of At The Market Program
WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram
|
||
acst |
Write Off Of Deferred Financing Costs Of At The Market Program
WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram
|
264000 | ||
acst |
Write Off Of Deferred Financing Costs Of At The Market Program
WriteOffOfDeferredFinancingCostsOfAtTheMarketProgram
|
|||
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001444192 | ||
CY2020Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
96892537 | |
dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | ||
dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | ||
dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | ||
dei |
Entity Registrant Name
EntityRegistrantName
|
Acasti Pharma Inc. | ||
dei |
Entity Shell Company
EntityShellCompany
|
false | ||
dei |
Entity Small Business
EntitySmallBusiness
|
true | ||
dei |
Security12b Title
Security12bTitle
|
Common Shares, no par value per share | ||
dei |
Trading Symbol
TradingSymbol
|
acst | ||
CY2020Q3 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
3670000 | |
CY2020Q1 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
7319000 | |
CY2020Q3 | us-gaap |
Accretion Expense
AccretionExpense
|
||
CY2019Q3 | us-gaap |
Accretion Expense
AccretionExpense
|
40000 | |
us-gaap |
Accretion Expense
AccretionExpense
|
|||
us-gaap |
Accretion Expense
AccretionExpense
|
77000 | ||
CY2020Q3 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-7400000 | |
CY2020Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-7887000 | |
CY2020Q3 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
10855000 | |
CY2020Q1 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
9797000 | |
CY2020Q3 | us-gaap |
Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
|
-1985000 | |
CY2019Q3 | us-gaap |
Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
|
-4908000 | |
us-gaap |
Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
|
-4974000 | ||
us-gaap |
Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
|
-12074000 | ||
us-gaap |
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
|
18000 | ||
CY2020Q3 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
319000 | |
CY2019Q3 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
482000 | |
us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
781000 | ||
us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
963000 | ||
CY2020Q3 | us-gaap |
Assets
Assets
|
13832000 | |
CY2020Q1 | us-gaap |
Assets
Assets
|
22853000 | |
CY2020Q3 | us-gaap |
Assets Current
AssetsCurrent
|
13713000 | |
CY2020Q1 | us-gaap |
Assets Current
AssetsCurrent
|
18462000 | |
CY2020Q3 | us-gaap |
Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
|
1047000 | |
CY2020Q1 | us-gaap |
Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
|
2578000 | |
CY2020Q3 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
||
CY2019Q3 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
219000 | |
us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
|||
us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
219000 | ||
CY2020Q3 | us-gaap |
Cash
Cash
|
6064000 | |
CY2019Q3 | us-gaap |
Cash
Cash
|
2615000 | |
CY2020Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
11552000 | |
CY2020Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
14240000 | |
CY2020Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
12122000 | |
CY2019Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
15977000 | |
CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
14240000 | |
CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
16871000 | |
CY2020Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
11552000 | |
CY2019Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
19496000 | |
CY2020Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-570000 | |
CY2019Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
3519000 | |
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-2688000 | ||
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
2625000 | ||
CY2020Q3 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
5488000 | |
CY2019Q3 | us-gaap |
Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
|
16881000 | |
CY2020Q3 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
2206031 | |
CY2020Q1 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
2206031 | |
CY2020Q3 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2020Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2020Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
142570000 | |
CY2020Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
137424000 | |
CY2020Q3 | us-gaap |
Deferred Costs Current
DeferredCostsCurrent
|
||
CY2020Q1 | us-gaap |
Deferred Costs Current
DeferredCostsCurrent
|
121000 | |
CY2020Q3 | us-gaap |
Depreciation
Depreciation
|
56000 | |
CY2019Q3 | us-gaap |
Depreciation
Depreciation
|
72000 | |
us-gaap |
Depreciation
Depreciation
|
142000 | ||
us-gaap |
Depreciation
Depreciation
|
161000 | ||
CY2020Q3 | us-gaap |
Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
|
1170000 | |
CY2020Q1 | us-gaap |
Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
|
2393000 | |
CY2020Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.06 | |
CY2019Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.25 | |
us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.11 | ||
us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.37 | ||
CY2020Q3 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
238000 | |
CY2019Q3 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
-190000 | |
us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
810000 | ||
us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
-137000 | ||
CY2020Q3 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-2027000 | |
CY2019Q3 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
14942000 | |
us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-1518000 | ||
us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
15874000 | ||
CY2020Q3 | us-gaap |
Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
|
-12000 | |
CY2019Q3 | us-gaap |
Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
|
-16000 | |
us-gaap |
Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
|
50000 | ||
us-gaap |
Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
|
40000 | ||
CY2020Q3 | us-gaap |
Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
|
20000 | |
CY2019Q3 | us-gaap |
Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
|
-64000 | |
us-gaap |
Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
|
154000 | ||
us-gaap |
Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
|
45000 | ||
CY2020Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1324000 | |
CY2019Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
1555000 | |
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2973000 | ||
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2671000 | ||
CY2020Q3 | us-gaap |
Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
|
3706000 | |
us-gaap |
Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
|
3706000 | ||
CY2019Q3 | us-gaap |
Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
|
||
us-gaap |
Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
|
|||
CY2020Q3 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
1584000 | |
CY2019Q3 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
||
us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
1584000 | ||
us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
|||
CY2020Q3 | us-gaap |
Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
|
1584000 | |
CY2019Q3 | us-gaap |
Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
|
||
us-gaap |
Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
|
1584000 | ||
us-gaap |
Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
|
|||
CY2020Q3 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-2348000 | |
CY2019Q3 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-1839000 | |
us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-3892000 | ||
us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-1651000 | ||
CY2020Q3 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-24000 | |
CY2019Q3 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
||
us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
-24000 | ||
us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
|||
CY2020Q3 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
-250000 | |
CY2019Q3 | us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
-185000 | |
us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
-544000 | ||
us-gaap |
Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
|
-556000 | ||
CY2020Q3 | us-gaap |
Increase Decrease In Receivables
IncreaseDecreaseInReceivables
|
119000 | |
CY2019Q3 | us-gaap |
Increase Decrease In Receivables
IncreaseDecreaseInReceivables
|
-427000 | |
us-gaap |
Increase Decrease In Receivables
IncreaseDecreaseInReceivables
|
47000 | ||
us-gaap |
Increase Decrease In Receivables
IncreaseDecreaseInReceivables
|
-227000 | ||
CY2020Q3 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
||
CY2020Q1 | us-gaap |
Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
|
4244000 | |
CY2020Q3 | us-gaap |
Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
|
||
CY2019Q3 | us-gaap |
Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
|
30000 | |
us-gaap |
Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
|
|||
us-gaap |
Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
|
60000 | ||
CY2020Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
15000 | |
CY2019Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
125000 | |
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
39000 | ||
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
228000 | ||
CY2020Q3 | us-gaap |
Liabilities
Liabilities
|
4959000 | |
CY2020Q1 | us-gaap |
Liabilities
Liabilities
|
9859000 | |
CY2020Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
13832000 | |
CY2020Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
22853000 | |
CY2020Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
3751000 | |
CY2020Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
7395000 | |
us-gaap |
Nature Of Operations
NatureOfOperations
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0" cellspacing="0" style="font-size: 10pt; font-weight: bold; margin-top: 0pt; margin-bottom: 0pt; min-width: 700px;"> <tr style="vertical-align: top"> <td style="width: 0.25in"></td> <td style="width: 0.25in"><div style="display: inline; font-style: italic; font: inherit;">1.</div></td> <td style="text-align: justify; padding-right: 5.65pt">Nature of Operation:</td> </tr> </table> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 5.9pt 0pt 0.5in"> </div> <div style=" margin: 0pt 5.9pt 0pt 0.5in; font-size: 10pt; text-align: justify">Acasti Pharma Inc. (“Acasti” or the “Corporation”) is incorporated under the Business Corporations Act (Québec) (formerly Part <div style="display: inline; font-style: italic; font: inherit;">1A</div> of the Companies Act (Québec)). The Corporation is domiciled in Canada and its registered office is located at <div style="display: inline; font-style: italic; font: inherit;">3009,</div> boul.de la Concord Est, Laval, Québec, <div style="display: inline; font-style: italic; font: inherit;">H7E</div> <div style="display: inline; font-style: italic; font: inherit;">2B5.</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 5.9pt 0pt 0.5in"> </div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 5.9pt 0pt 0.5in">In <div style="display: inline; font-style: italic; font: inherit;"> August 2020, </div>the Corporation released Phase <div style="display: inline; font-style: italic; font: inherit;">3</div> clinical study results for the Corporation's lead drug candidate, CaPre. The failure of the studies to meet the primary endpoint resulted in the Corporation making a decision <div style="display: inline; font-style: italic; font: inherit;">not</div> to proceed with a filing of a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA).</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 5.9pt 0pt 0.5in"> </div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 5.9pt 0pt 0.5in">In <div style="display: inline; font-style: italic; font: inherit;"> September 2020, </div>the Corporation has commenced a formal process to explore and evaluate strategic alternatives to enhance shareholder value. Towards this end, the Corporation has engaged a financial advisor to assist in the process. There can be <div style="display: inline; font-style: italic; font: inherit;">no</div> assurance of a successful outcome from these efforts, or of the form or timing of any such outcome. The Corporation has greatly reduced its research and development activities including a reduction in workforce to reduce operating expenses, while it evaluates these opportunities. The Corporation's operations are now primarily focused on evaluating these opportunities. The Corporation remains subject to a number of risks similar to other companies in the biotechnology industry, including compliance with government regulations, protection of proprietary technology, dependence on <div style="display: inline; font-style: italic; font: inherit;">third</div> parties and product liability.</div></div> | ||
CY2020Q3 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
3434000 | |
CY2019Q3 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
6596000 | |
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
5067000 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
6596000 | ||
CY2020Q3 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-33000 | |
CY2019Q3 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
3366000 | |
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-69000 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
8884000 | ||
CY2020Q3 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-4178000 | |
CY2019Q3 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-6152000 | |
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-8345000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-12942000 | ||
CY2020Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-4666000 | |
CY2020Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-6146000 | |
CY2019Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-8846000 | |
CY2019Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-21158000 | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-10812000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-30004000 | ||
CY2020Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
1888000 | |
CY2019Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-14903000 | |
us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
1343000 | ||
us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-15743000 | ||
CY2020Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-8034000 | |
CY2019Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-6255000 | |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-12155000 | ||
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-14261000 | ||
CY2020Q3 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
81000 | |
CY2020Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
76000 | |
CY2020Q3 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
38000 | |
CY2020Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
71000 | |
CY2020Q3 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
119000 | |
CY2020Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
147000 | |
CY2020Q2 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
308000 | |
CY2020Q3 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
179000 | |
CY2019Q2 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
51000 | |
CY2019Q3 | us-gaap |
Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
|
-64000 | |
CY2020Q3 | us-gaap |
Paid In Kind Interest
PaidInKindInterest
|
||
CY2019Q3 | us-gaap |
Paid In Kind Interest
PaidInKindInterest
|
40000 | |
us-gaap |
Paid In Kind Interest
PaidInKindInterest
|
|||
us-gaap |
Paid In Kind Interest
PaidInKindInterest
|
77000 | ||
CY2020Q3 | us-gaap |
Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
|
33000 | |
CY2019Q3 | us-gaap |
Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
|
17000 | |
us-gaap |
Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
|
69000 | ||
us-gaap |
Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
|
36000 | ||
CY2020Q3 | us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
1000 | |
CY2019Q3 | us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
36000 | |
us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
143000 | ||
us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
36000 | ||
CY2020Q3 | us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
21000 | |
CY2019Q3 | us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
11000 | |
us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
21000 | ||
us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
2030000 | ||
CY2020Q3 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
489000 | |
CY2020Q1 | us-gaap |
Prepaid Expense Current
PrepaidExpenseCurrent
|
977000 | |
CY2020Q3 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
3435000 | |
CY2019Q3 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
||
us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
5210000 | ||
us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
|||
CY2020Q3 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
|
21000 | |
CY2019Q3 | us-gaap |
Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
|
3394000 | |
us-gaap |
Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
|
21000 | ||
us-gaap |
Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
|
10950000 | ||
CY2020Q3 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
||
CY2019Q3 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
13000 | |
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
|||
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
13000 | ||
CY2020Q3 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
||
CY2019Q3 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
6619000 | |
us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
|||
us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
6619000 | ||
CY2020Q3 | us-gaap |
Receivables Net Current
ReceivablesNetCurrent
|
625000 | |
CY2020Q1 | us-gaap |
Receivables Net Current
ReceivablesNetCurrent
|
546000 | |
CY2020Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
1286000 | |
CY2019Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
3954000 | |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
3042000 | ||
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
10144000 | ||
CY2020Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-137152000 | |
CY2020Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-126340000 | |
CY2020Q3 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
134000 | |
CY2019Q3 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
746000 | |
us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
850000 | ||
us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
1446000 | ||
CY2020Q3 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
401000 | |
CY2019Q3 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
650000 | |
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1033000 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
900000 | ||
CY2020Q2 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
1765000 | |
CY2020Q3 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
3427000 | |
CY2020Q2 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
635000 | |
CY2020Q3 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
377000 | |
CY2019Q2 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
252000 | |
CY2019Q3 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
670000 | |
CY2020Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
12994000 | |
CY2020Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
11036000 | |
CY2020Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
8873000 | |
CY2019Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
11045000 | |
CY2019Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
3275000 | |
CY2019Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-759000 | |
us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in"><div style="display: inline; font-weight: bold;">Use of estimates</div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in"><div style="display: inline; font-weight: bold;"> </div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, income and expenses. Actual results <div style="display: inline; font-style: italic; font: inherit;"> may </div>differ from these estimates.</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in"> </div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in">Estimates are based on management's best knowledge of current events and actions that management <div style="display: inline; font-style: italic; font: inherit;"> may </div>undertake in the future. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in"> </div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0 0pt 0.5in">Estimates and assumptions include the measurement of derivative warrant liabilities (note <div style="display: inline; font-style: italic; font: inherit;">6</div>) and stock-based compensation (note <div style="display: inline; font-style: italic; font: inherit;">10</div>), impairment of intangibles and assets held for sale (notes <div style="display: inline; font-style: italic; font: inherit;">4</div> and <div style="display: inline; font-style: italic; font: inherit;">5</div>) and the take-or-pay contract (note <div style="display: inline; font-style: italic; font: inherit;">12</div>(a)). Estimates and assumptions are also involved in measuring the accrual of services rendered with respect to research and developments expenditures at each reporting date, as well as in determining which research and development expenses qualify for investment tax credits and in what amounts. The Corporation recognizes the tax credits once it has reasonable assurance that they will be realized. Recorded tax credits are subject to review and approval by tax authorities and, therefore, could be different from the amounts recorded.</div></div></div> | ||
CY2020Q3 | us-gaap |
Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
|
881000 | |
CY2020Q1 | us-gaap |
Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
|
881000 | |
CY2020Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
95119503 | |
CY2019Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
83092037 | |
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
92917712 | ||
us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
80877225 |